Replies to post #37029 on Humanigen Inc (fka HGENQ)

[OneDay4488]

The market does at .46 cents

[cowtown jay]

Yes, dlog, I understand and recognized that lenz prevents cytokine storm.

And in disclosing that Biden had contracted covid, despite vaccinations and boosters, I also said that lenz was, "...available to help prevent that recurrence."

I see why eb took my comment to mean I was saying lenz could have prevented covid reinfection.

Quite the contrary, I recognize that lenz is only effective once a patient has some form of the virus.

We know that vaccinated patients can suffer breakthrough infections. So the first question is, how many lenz patients have suffered breakthrough infections?

Secondly, evidence is pointing to the fact that the virus is finding ways to escape Paxlovid.

"The resistance studies come on the heels of other recent concerns about Paxlovid, which in the United States remains restricted to use in people with risk factors making them more likely to develop severe COVID-19. Confirming anecdotal reports widely reported by media, several studies have found a small percentage of infected people who receive the normal 5-day course initially feel better, only to have their symptoms rebound. And questions have grown about whether Paxlovid helps those who aren’t at high risk of serious disease—Pfizer earlier this month halted a large trial of the drug in standard risk COVID-19 patients because it was failing to show statistically significant protection against death or hospitalization...

However, the recent studies suggest the virus is poised to develop resistance—a fate that befalls many antiviral drugs. Two preprints posted on bioRxiv on 7 June, for example, show that SARS-coV-2 grown in the lab quickly gains the ability to avoid nirmatrelvir’s (Paxlovid component) attack. Two research groups independently cultured the coronavirus with low levels of nirmatrelvir, killing some but not all of the virus. Such tests are meant to simulate what might happen in an infected person who doesn’t take the whole regimen of the drug or an immunocompromised patient who has trouble clearing the virus...

Indeed, some of these mutations are already in coronavirus-infected people, according to work by Adam Godzik, a bioinformatics expert at the University of California, Riverside..."

excellent article:

https://www.science.org/content/article/bad-news-paxlovid-coronavirus-can-find-multiple-ways-evade-covid-19-drug?cookieSet=1

So the second question is shaping up to be, how many Paxlovid (anti-viral) patients are suffering breakthrough infections?